Collegium Pharmaceutical Inc (COLL) to Post Q1 2019 Earnings of ($0.43) Per Share, William Blair Forecasts

Share on StockTwits

Collegium Pharmaceutical Inc (NASDAQ:COLL) – Investment analysts at William Blair reduced their Q1 2019 earnings per share (EPS) estimates for shares of Collegium Pharmaceutical in a note issued to investors on Tuesday, January 8th. William Blair analyst T. Lugo now expects that the specialty pharmaceutical company will earn ($0.43) per share for the quarter, down from their prior forecast of ($0.40). William Blair also issued estimates for Collegium Pharmaceutical’s Q2 2019 earnings at ($0.24) EPS, Q3 2019 earnings at ($0.18) EPS, Q4 2019 earnings at ($0.11) EPS, FY2019 earnings at ($0.96) EPS and FY2020 earnings at $0.73 EPS.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its earnings results on Thursday, November 8th. The specialty pharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.36) by ($0.14). Collegium Pharmaceutical had a negative return on equity of 70.06% and a negative net margin of 30.13%. The firm had revenue of $70.20 million for the quarter, compared to analyst estimates of $74.79 million. During the same period in the previous year, the company posted ($0.45) EPS. Collegium Pharmaceutical’s revenue was up 485.0% on a year-over-year basis.

COLL has been the topic of a number of other research reports. ValuEngine lowered Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Monday. BidaskClub raised Collegium Pharmaceutical from a “strong sell” rating to a “sell” rating in a research report on Thursday, October 4th. Zacks Investment Research lowered Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Tuesday, October 23rd. Cantor Fitzgerald set a $35.00 price target on Collegium Pharmaceutical and gave the company a “buy” rating in a research report on Friday, November 30th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Collegium Pharmaceutical in a research report on Monday, September 17th. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $30.43.

COLL stock opened at $15.21 on Thursday. The company has a current ratio of 0.78, a quick ratio of 0.75 and a debt-to-equity ratio of 4.17. The stock has a market capitalization of $622.39 million, a price-to-earnings ratio of -6.16 and a beta of 0.52. Collegium Pharmaceutical has a 1 year low of $13.70 and a 1 year high of $29.90.

A number of large investors have recently added to or reduced their stakes in COLL. Vanguard Group Inc grew its stake in shares of Collegium Pharmaceutical by 9.0% in the 3rd quarter. Vanguard Group Inc now owns 1,375,709 shares of the specialty pharmaceutical company’s stock valued at $20,278,000 after purchasing an additional 113,038 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Collegium Pharmaceutical by 9.0% in the 3rd quarter. Vanguard Group Inc. now owns 1,375,709 shares of the specialty pharmaceutical company’s stock valued at $20,278,000 after buying an additional 113,038 shares during the period. Morgan Stanley lifted its holdings in shares of Collegium Pharmaceutical by 20.1% in the 3rd quarter. Morgan Stanley now owns 1,056,133 shares of the specialty pharmaceutical company’s stock valued at $15,566,000 after buying an additional 176,577 shares during the period. Teachers Advisors LLC lifted its holdings in shares of Collegium Pharmaceutical by 6.2% in the 3rd quarter. Teachers Advisors LLC now owns 77,036 shares of the specialty pharmaceutical company’s stock valued at $1,136,000 after buying an additional 4,484 shares during the period. Finally, MetLife Investment Advisors LLC acquired a new stake in shares of Collegium Pharmaceutical in the 3rd quarter valued at approximately $339,000.

In other news, Director Michael Thomas Heffernan sold 25,000 shares of the firm’s stock in a transaction dated Monday, October 15th. The stock was sold at an average price of $16.53, for a total transaction of $413,250.00. Following the sale, the director now owns 361,000 shares of the company’s stock, valued at approximately $5,967,330. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold a total of 75,000 shares of company stock worth $1,282,750 in the last three months. Corporate insiders own 13.87% of the company’s stock.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing, and/or dissolving.

Featured Article: Risk Tolerance

Earnings History and Estimates for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Legg Mason Inc  Receives $37.05 Consensus Target Price from Analysts
Legg Mason Inc Receives $37.05 Consensus Target Price from Analysts
Analysts Set Broadridge Financial Solutions, Inc.  Price Target at $108.40
Analysts Set Broadridge Financial Solutions, Inc. Price Target at $108.40
Endorsit  1-Day Trading Volume Reaches $1,563.00
Endorsit 1-Day Trading Volume Reaches $1,563.00
Maximine Coin  Price Hits $0.0119
Maximine Coin Price Hits $0.0119
Contrasting Gafisa  & Xinyuan Real Estate
Contrasting Gafisa & Xinyuan Real Estate
Pershing Gold Corp  Given $3.63 Consensus Target Price by Analysts
Pershing Gold Corp Given $3.63 Consensus Target Price by Analysts


Leave a Reply

© 2006-2019 Ticker Report